-- 聯合包裹服務公司 (UPS) 旗下的 Roadie 部門週三宣布，已將其服務與 Centiro 的配送管理平台整合，以支持大型零售商和第三方物流公司實現當日送達。 該公司表示，此次合作利用 RoadieXD 交叉轉運系統，透過將標籤列印與貨運資料傳輸分離，消除高峰期的倉庫瓶頸。 Roadie 補充道，工作人員可以使用現有工作流程列印貨運標籤，而配送資料則按計畫批次傳輸到配送網絡，從而保持配送速度並降低成本。
Price: $102.71, Change: $-0.52, Percent Change: -0.50%
Adobe (ADBE) has an average rating of overweight and mean price target of $321.05, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)
Organon (OGN) shares spiked early Monday after the healthcare company agreed to be acquired by Indian pharmaceutical firm Sun Pharmaceutical Industries in an all-cash deal with an enterprise value of about $11.75 billion.Shareholders of Organon will receive $14 a share in cash under the terms of the transaction, the companies said in a joint statement on Sunday. Organon's stock jumped 15% in the most recent premarket activity."Following a comprehensive review of strategic alternatives, our board determined that this all-cash transaction offers compelling and immediate value to Organon stockholders," Organon Chief Executive Carrie Cox said in the statement. "We believe Sun Pharma is well positioned to support Organon's businesses, employees and patients globally."Organon, which focuses on women's health, was formed in 2021 following its separation from pharmaceutical giant Merck (MRK).The deal, which requires approval from regulators and clearance from Organon's shareholders, is expected to complete early next year."This transaction is a logical next step in strengthening Sun Pharma's global business," according to Sun Pharma Managing Director Kirti Ganorkar. "In addition, there is a scope for synergies including significant revenue upside opportunities to be realized over the coming years."Sun Pharma intends to fund the acquisition through a combination of available cash resources and committed financing from banks. The Indian company anticipates the transaction to allow it to enter the biosimilar market.For the year ended Dec. 31, Organon reported revenue of $6.22 billion and adjusted earnings before interest, taxes, depreciation and amortization of $1.91 billion. In February, the company said it expected revenue of $6.2 billion for the current year, while five analysts polled by FactSet estimate $6.15 billion.